The European Commission recently launched a targeted stakeholders consultation on the revision of Annex 1, on manufacturing of sterile medicinal products, of the Eudralex Volume 4. EIPG has reviewed the document and, following feedback from its members, has submitted its comments to the EMA.
-
-
News from EIPG
- Environmental sustainability: the EIPG perspective
- How AI is Changing the Pharma Industry and the Industrial Pharmacist’s Role
- Generative AI in drug development
- PGEU annual medicine shortages report
- EMA’s pilot scheme for academic and non-profit development of ATMPs
- Lessons learnt to transition from Horizon 2020 to the new FP10
- Approvals and flops in drug development in 2023